(BDX) Becton Dickinson - Ratings and Ratios
Medical Supplies, Laboratory Equipment, Diagnostic Products, Syringes, Needles
BDX EPS (Earnings per Share)
BDX Revenue
Description: BDX Becton Dickinson
Becton Dickinson and Company (NYSE:BDX) is a global medical technology company that develops, manufactures, and sells a wide range of medical supplies, devices, and diagnostic products. The companys diverse product portfolio is designed to meet the needs of various healthcare stakeholders, including healthcare institutions, physicians, researchers, and patients.
The companys business is organized into three main segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical provides a range of medical devices and solutions, including vascular access technology, medication safety systems, and prefillable drug delivery systems. BD Life Sciences offers a variety of products and services for life science research, including specimen collection products, automated blood culturing systems, and fluorescence-activated cell sorters. BD Interventional provides surgical products, including hernia repair solutions, biosurgery products, and peripheral intervention products.
From a financial perspective, BDX has a market capitalization of over $50 billion, indicating a significant presence in the healthcare industry. The companys return on equity (ROE) is around 5.86%, which is a relatively modest return. To improve profitability, BDX may need to focus on optimizing its product mix, improving operational efficiency, and investing in growth initiatives. Key performance indicators (KPIs) to watch include revenue growth, gross margin expansion, and research and development (R&D) investment as a percentage of sales.
In terms of growth prospects, BDX operates in a large and growing market driven by increasing demand for healthcare services, aging populations, and the need for innovative medical technologies. The companys strong brand reputation, extensive distribution network, and commitment to R&D position it well to capitalize on these trends. To drive future growth, BDX may need to continue investing in emerging technologies, such as digital health and personalized medicine, and expanding its presence in high-growth markets.
BDX Stock Overview
| Market Cap in USD | 54,347m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1987-01-01 |
BDX Stock Ratings
| Growth Rating | -44.5% |
| Fundamental | 62.7% |
| Dividend Rating | 53.7% |
| Return 12m vs S&P 500 | -31.6% |
| Analyst Rating | 3.59 of 5 |
BDX Dividends
| Dividend Yield 12m | 2.05% |
| Yield on Cost 5y | 1.99% |
| Annual Growth 5y | 4.50% |
| Payout Consistency | 81.2% |
| Payout Ratio | 29.2% |
BDX Growth Ratios
| Growth Correlation 3m | 81.4% |
| Growth Correlation 12m | -78% |
| Growth Correlation 5y | -8.3% |
| CAGR 5y | -7.11% |
| CAGR/Max DD 3y | -0.18 |
| CAGR/Mean DD 3y | -0.49 |
| Sharpe Ratio 12m | -0.44 |
| Alpha | 0.00 |
| Beta | 0.978 |
| Volatility | 21.94% |
| Current Volume | 1211.5k |
| Average Volume 20d | 1567.4k |
| Stop Loss | 180.6 (-3%) |
| Signal | -0.12 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (1.61b TTM) > 0 and > 6% of Revenue (6% = 1.28b TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -1.15pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3.91% (prev 28.25%; Δ -24.34pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 3.25b > Net Income 1.61b (YES >=105%, WARN >=100%) |
| Net Debt (18.61b) to EBITDA (4.80b) ratio: 3.87 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.10 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (288.7m) change vs 12m ago -0.54% (target <= -2.0% for YES) |
| Gross Margin 45.08% (prev 42.06%; Δ 3.02pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 38.71% (prev 35.67%; Δ 3.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.12 (EBITDA TTM 4.80b / Interest Expense TTM 613.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.92
| (A) 0.02 = (Total Current Assets 9.00b - Total Current Liabilities 8.16b) / Total Assets 54.90b |
| (B) 0.30 = Retained Earnings (Balance) 16.43b / Total Assets 54.90b |
| (C) 0.05 = EBIT TTM 2.53b / Avg Total Assets 55.24b |
| (D) 0.51 = Book Value of Equity 14.98b / Total Liabilities 29.43b |
| Total Rating: 1.92 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 62.65
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 3.50% = 1.75 |
| 3. FCF Margin 11.92% = 2.98 |
| 4. Debt/Equity 0.76 = 2.22 |
| 5. Debt/Ebitda 4.03 = -2.50 |
| 6. ROIC - WACC -2.48% = -3.10 |
| 7. RoE 6.31% = 0.53 |
| 8. Rev. Trend 85.86% = 6.44 |
| 9. EPS Trend 76.50% = 3.83 |
What is the price of BDX shares?
Over the past week, the price has changed by -2.25%, over one month by -3.99%, over three months by +8.79% and over the past year by -18.77%.
Is Becton Dickinson a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BDX is around 167.04 USD . This means that BDX is currently overvalued and has a potential downside of -10.29%.
Is BDX a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 208 | 11.7% |
| Analysts Target Price | 208 | 11.7% |
| ValueRay Target Price | 184.2 | -1.1% |
Last update: 2025-09-05 04:34
BDX Fundamental Data Overview
CCE Cash And Equivalents = 757.0m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 34.7271
P/E Forward = 12.2399
P/S = 2.5413
P/B = 2.1171
P/EG = 0.9413
Beta = 0.224
Revenue TTM = 21.39b USD
EBIT TTM = 2.53b USD
EBITDA TTM = 4.80b USD
Long Term Debt = 17.53b USD (from longTermDebt, last quarter)
Short Term Debt = 1.81b USD (from shortTermDebt, last quarter)
Debt = 19.34b USD (Calculated: Short Term 1.81b + Long Term 17.53b)
Net Debt = 18.61b USD (from netDebt column, last quarter)
Enterprise Value = 72.93b USD (54.35b + Debt 19.34b - CCE 757.0m)
Interest Coverage Ratio = 4.12 (Ebit TTM 2.53b / Interest Expense TTM 613.0m)
FCF Yield = 3.50% (FCF TTM 2.55b / Enterprise Value 72.93b)
FCF Margin = 11.92% (FCF TTM 2.55b / Revenue TTM 21.39b)
Net Margin = 7.51% (Net Income TTM 1.61b / Revenue TTM 21.39b)
Gross Margin = 45.08% ((Revenue TTM 21.39b - Cost of Revenue TTM 11.74b) / Revenue TTM)
Tobins Q-Ratio = 4.87 (Enterprise Value 72.93b / Book Value Of Equity 14.98b)
Interest Expense / Debt = 0.79% (Interest Expense 152.0m / Debt 19.34b)
Taxrate = 14.96% (300.0m / 2.00b)
NOPAT = 2.15b (EBIT 2.53b * (1 - 14.96%))
Current Ratio = 1.10 (Total Current Assets 9.00b / Total Current Liabilities 8.16b)
Debt / Equity = 0.76 (Debt 19.34b / last Quarter total Stockholder Equity 25.47b)
Debt / EBITDA = 4.03 (Net Debt 18.61b / EBITDA 4.80b)
Debt / FCF = 7.58 (Debt 19.34b / FCF TTM 2.55b)
Total Stockholder Equity = 25.45b (last 4 quarters mean)
RoA = 2.93% (Net Income 1.61b, Total Assets 54.90b )
RoE = 6.31% (Net Income TTM 1.61b / Total Stockholder Equity 25.45b)
RoCE = 5.88% (Ebit 2.53b / (Equity 25.45b + L.T.Debt 17.53b))
RoIC = 4.79% (NOPAT 2.15b / Invested Capital 44.82b)
WACC = 7.27% (E(54.35b)/V(73.69b) * Re(9.62%)) + (D(19.34b)/V(73.69b) * Rd(0.79%) * (1-Tc(0.15)))
Shares Correlation 3-Years: 21.21 | Cagr: 0.07%
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 74.59% ; FCFE base≈2.82b ; Y1≈3.16b ; Y5≈4.20b
Fair Price DCF = 192.9 (DCF Value 55.29b / Shares Outstanding 286.6m; 5y FCF grow 13.83% → 3.0% )
EPS Correlation: 76.50 | EPS CAGR: 11.17% | SUE: 1.86 | # QB: 1
Revenue Correlation: 85.86 | Revenue CAGR: 5.45%
Additional Sources for BDX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle